bluuebunny/crossref_metadata_2025_split huggingface dataset:
JADES Data Release 3: NIRSpec/Microshutter Assembly Spectroscopy for 4000 Galaxies in the GOODS Fields
Authors: D’Eugenio Francesco , Cameron Alex J. , Scholtz Jan , Carniani Stefano , Willott Chris J. , Curtis-Lake Emma , Bunker Andrew J. , Parlanti Eleonora , Maiolino Roberto , Willmer Christopher N. A. , Jakobsen Peter , Robertson Brant E. , Johnson Benjamin D. , Tacchella Sandro , Cargile Phillip A. , Rawle Tim , Arribas Santiago , Chevallard Jacopo , Curti Mirko , Egami Eiichi , Eisenstein Daniel J. , Kumari Nimisha , Looser Tobias J. , Rieke Marcia J. , Rodríguez Del Pino Bruno , Saxena Aayush , Übler Hannah , Venturi Giacomo , Witstok Joris , Baker William M. , Bhatawdekar Rachana , Bonaventura Nina , Boyett Kristan , Charlot Stephane , Danhaive A. Lola , Hainline Kevin N. , Hausen Ryan , Helton Jakob M. , Ji Xihan , Ji Zhiyuan , Jones Gareth C. , Juodžbalis Ignas , Maseda Michael V. , Pérez-González Pablo G. , Perna Michele , Puskás Dávid , Shivaei Irene , Silcock Maddie S. , Simmonds Charlotte , Smit Renske , Sun Fengwu , Villanueva Natalia C. , Williams Christina C. , Zhu Yongda 
Published: February 2025

Abstract
We present the third data release of the JWST Advanced Deep Extragalactic Survey (JADES), providing both imaging and spectroscopy in the two GOODS fields. Spectroscopy consists of medium-depth and deep NIRSpec/microshutter assembly spectra of 4000 targets, covering the spectral range 0.6–5.3 μm and observed with both the low-dispersion prism (R = 30–300) and all three medium-resolution gratings (R = 500–1500). We describe the observations, data reduction, sample selection, and target allocation. We measured 2375 redshifts (2053 from multiple emission lines); our targets span the range from z = 0.5 up to z = 13, including 404 at z > 5. The data release includes 2D and 1D fully reduced spectra, with slit-loss corrections and background subtraction optimized for point sources. We also provide redshifts and signal-to-noise ratio > 5 emission-line flux catalogs for the prism and grating spectra, and concise guidelines on how to use these data products. Alongside spectroscopy, we are also publishing fully calibrated NIRCam imaging, which enables studying the JADES sample with the combined power of imaging and spectroscopy. Together, these data provide the largest statistical sample to date to characterize the properties of galaxy populations in the first billion years after the Big Bang.
Cytomegalovirus in Autoimmune Disease: Insights and Implications
Authors: Baliga Sahana , Samant Rohini 
Published: February 2025

Abstract
Cytomegalovirus (CMV), a DNA virus within the herpesviridae family, possesses an extensive genome with over 700 open reading frames. The virus establishes latency in the host’s myeloid precursor cells and, while often asymptomatic in immunocompetent individuals. CMV’s large proteome, lytic replication cycle, persistence, and reactivation, along with its ability to modulate the immune system, make it a potential etiological factor in autoimmune diseases (ADs). Research has demonstrated an association between CMV and the onset or exacerbation of ADs. Key mechanisms, such as molecular mimicry – exemplified by UL94 in systemic sclerosis and UL83/PP65 in systemic lupus erythematosus – and the expansion of proinflammatory CD28-null cells, have been implicated in CMV-related autoimmunity. In addition, CMV infection is frequently linked to increased autoantibody production, a critical factor in the pathogenesis of AD. Despite these associations, a definitive causal relationship between CMV seroprevalence and AD remains unestablished. Not all individuals with CMV viral load develop ADs; rather, disease manifestation occurs primarily in those with specific high-risk factors. This review will provide a concise overview of the mechanisms underlying CMV-induced autoimmunity, the risk factors for CMV infection, and its association with specific rheumatological conditions.
DMARD Adherence in Rheumatoid Arthritis Patients: A Cross-sectional Study from the Coastal Part of Kerala
Authors: Jalal Muhammed Jasim Abdul 
Published: February 2025

Abstract

Aim of the study:
The aim of this study was to determine sociodemographic and disease traits in rheumatoid arthritis (RA) patients.

Study Design and Study Subjects:
This is a cross-sectional study conducted in the Rheumatology Department at the Olive Healthcare Polyclinic located in the coastal part of Thrissur, Kerala, India, between December 2023 and February 2024.

Study Methods:
1. Sociodemographic and disease traits. Sociodemographic factors such as age, sex, marital status, educational level, and monthly net income were studied. Clinical factors such as disease duration, RA treatment, and number of other medications taken were measured. 2. Self-disclosed treatment compliance. The RA patient’s treatment compliance was assessed using the Medication Adherence Report Scale (MARS-5), which is a short version of the MARS. 3. Statistic assessment. All statistical analyses were performed using IBM SPSS Statistics, version 22.0. 4. Ethical considerations. Ethical Board and Scientific Board, Olive Healthcare, approved this study.

Results:
Fifty-five patients were completely compliant to the DMARD medications. Factors such as female sex, older age, monthly net income between Rs. 10,000 and Rs. 20,000, and disease duration less than 10 years were associated with higher medication compliance.

Conclusion:
Factors such as old age, female gender, income, and disease duration were associated with an increased risk for DMARD medication non-adherence.
Comparison of i-gel®, Ambu® AuraGain™, Baska Mask, LMA® Protector™ for airway management of obese surgical patients - A randomised comparative study
Authors: Raman Rajesh , Gupta Apoorva , Prabha Rati , Gautam Shefali , Anand Akshay 
Published: February 2025

Background and Aims:
A few trials have studied the use of supraglottic airway devices (SADs) for obese patients. This trial aimed to compare four SADs: I-gel, Ambu AuraGain, Baska mask, and Laryngeal Mask Airway (LMA) Protector for airway management of obese patients.

Methods:
This parallel-group, single-blind, comparative randomised study included 154 obese patients aged between 18 and 60 years who were planned for elective surgery. They were randomly allocated one of the above four SADs for airway management. Each group had 38 patients. The allocated SAD was inserted after induction of anaesthesia. oropharyngeal leak pressure (OLP) was the primary outcome. Data were analysed using analysis of variance, Kruskal-Wallis, or χ2 test.

Results:
Baseline data of the patients were comparable. Mean OLP was highest with the Baska mask and lowest with the LMA Protector [32.97 (standard deviation (SD): 1.30) (95% confidence interval (CI): 32.54, 33.40] vs 30.08 (SD: 1.51) (95% CI: 29.58, 30.58) cm H2O). The mean leak fraction was highest with the Baska mask and lowest with Ambu AuraGain (6.88 (SD: 1.33) (95% CI: 6.44, 7.31) vs 6.08 (SD: 1.18) (95% CI: 5.69, 6.47)). The mean time taken to insert the SAD was shortest with I-gel and longest with Ambu AuraGain (18.58 (SD: 1.97) (95% CI: 17.93, 19.23) vs 29.11 (SD: 2.50) (95% CI: 28.28, 29.93) sec). Heart rate, SAD placement success rate, fibreoptic view of the glottis, blood pressure, and side effects were comparable amongst the devices.

Conclusion:
For obese patients undergoing elective surgery, the Baska mask has the highest OLP, but I-gel, Ambu AuraGain, and LMA Protector are also acceptable choices.
A randomised controlled trial comparing video laryngoscopy versus conventional blind technique for transoesophageal echocardiography probe insertion in paediatric patients undergoing cardiac surgery: A pilot study
Authors: Singh Guriqbal , Pujara Jigisha , Chauhan Ankit , Rajesh Venuthurupalli S. P. , Sonune Shrikant , Kumar Jamalpur Sravan , Pandya Himani 
Published: February 2025

Background and Aims:
Inserting a transoesophageal echocardiography (TEE) probe can cause pharyngeal and oesophageal injuries in paediatric patients undergoing cardiac surgery. The study’s primary objective was to assess the incidence of oropharyngeal injury on video laryngoscope (VL) examination at the end of surgery.

Methods:
This randomised controlled study was conducted on 100 patients, aged 2–10 years, undergoing elective cardiac surgery requiring TEE evaluation. Patients having a deranged coagulation profile, sore throat, difficult tracheal intubation, trauma during tracheal intubation and contraindications for TEE insertion were excluded from the study. Patients were randomised into the conventional group (Group C; n = 50), where the TEE probe was inserted using the conventional blind insertion technique, and the VL group (Group VL; n = 50). All patients were examined with VL for oropharyngeal injury after removal of the TEE probe at the completion of surgery, and the injury site was documented.

Results:
The incidence of pharyngeal mucosal injury was significantly lesser in Group VL (n = 2) than in the Group C (n = 9) (P = 0.025). The number of attempts for successful TEE probe insertion was significantly lower in Group VL (P < 0.05). The mean duration for successful TEE probe insertion at the first attempt was significantly longer in Group VL than in Group C (P < 0.0001).

Conclusion:
The use of VL for TEE probe insertion in paediatric patients significantly reduced the incidence of pharyngeal injury related to its insertion and provided direct visualisation of the oesophageal inlet.
Myeloid sarcoma of the small intestine in nonleukemic patients – A report of three cases with review of literature
Authors: Thingujam Bipin S. , Irom Anil , Thangjam Babina , Howdijam David , Srivastava Ritika , Takhellambam Dipdeba 
Published: February 2025

Abstract

Background:
Granulocytic sarcoma (GS) or myeloid sarcoma (MS) is a tumor of hematopoietic stem cell origin composed of myeloblasts or immature myeloid cells presenting as tumor masses in an extramedullary site. The tumor can affect any site of the body but are commonly seen in the skin, bone and lymph node. It may develop de novo or concurrently with acute myeloid leukemia (AML), myeloproliferative disorder (MPD) or myelodysplastic syndrome (MDS). MS may precede AML by months or years or present as an initial manifestation of relapse in a previously treated AML in remission. On light microscopic examination, based on histological features cases of MS are frequently erroneously diagnosed, more so in non-leukaemic patients, as non-Hodgkin lymphoma (NHL) or undifferentiated carcinoma. Immunophenotyping is needed for a diagnosis of MS. A variety of chromosomal abnormalities are reported; particularly t(8;21)(q22;q22), which is regarded as a recurrent aberration in MS. Only a few cases of MS of the small intestine in non-leukaemic patients, defined by the absence of a history of leukemia, myelodysplastic syndrome (MDS), or myeloproliferative neoplasm along with a negative bone marrow biopsy, are described in literature. Treatment strategies are still not well defined.

Methods:
We analyse and describe 3 cases of patients with MS involving the intestine and describe the histological diagnostic pointers, clinicopathologic and immunophenotypic features.

Results:
Granulocytic sarcoma has definite well recognisable diagnostic features. The characteristic features include: tumor cells arranged in sheets and in occasional infiltrating singles; absence of necrosis; starry-sky appearance; scattered eosinophils & promyelocytes; tumor cells negative for CD3, CD20, while being positive for CD45 (patchy) and CD19.

Conclusions:
Granulocytic sarcoma is a rare disease and a high index of suspicion is needed for making a correct diagnosis. Judicious use of immunohistochemistry helps in coming to a diagnosis. We propose a diagnostic algorithm for making a diagnosis of granulocytic sarcoma.
Safety of Endostar in combination with chemotherapy in patients with cancer
Authors: Wang Dong-Xiao , Zhu Man , Guo Dai-Hong , Gu Jin , Xia Lei , Huang Xiao-Wu , Wang Tian-Lin , Zhao Chang-Hong 
Published: February 2025

Abstract

Background:
Several studies have indicated the benefits and safety of Endostar in combination with chemotherapy, but the exact real-life safety of Endostar is poorly known. This study aimed to assess the safety of Endostar in combination with chemotherapy in a real-life setting in China.

Materials and Methods:
This was a retrospective study of patients treated with Endostar combined with chemotherapy from January 1, 2006, to December 31, 2017. Data were obtained from the Hospital Information System (HIS). Laboratory abnormalities were evaluated according to Common Terminology Criteria for Adverse Events, Version 4.0. Bleeding events and wound complications after surgery associated with Endostar were evaluated.

Results:
Finally, 825 patients were included. No patients used Endostar alone. Anemia occurred in 74.5% of the patients, thrombocytopenia in 29.0%, abnormal white blood cell counts in 54.5%, abnormal liver function in 13.8%, and increased creatinine in 1.2%. No definite bleeding events and wound complications associated with Endostar were found. Most laboratory adverse effects (AEs) were found in Grades 1 and 2. Lung cancer, osteosarcoma, and doxorubicin-based chemotherapy were associated with an increased risk of Grade ≥3 abnormal white blood cell counts. The total dose of Endostar was not associated with severe (Grade ≥3) thrombocytopenia and abnormal white blood cell counts.

Conclusion:
The occurrence of AEs during Endostar and chemotherapy treatment differed across different tumor types and chemotherapy regimens. No new unexpected Endostar-related AEs were observed. The total dose of Endostar was not associated with an increased risk of severe (Grade ≥3) thrombocytopenia and abnormal white blood cell counts when used in combination with chemotherapy in the real-life setting.
Frequency and clinical significance of human papilloma virus in oral cancer - A study from Kerala
Authors: Raj Divya , George Preethi Sara , Lakshmi S , Kumar R Rejnish , Thommachan Kainickal Cessel , Rafi Malu , Anantharaman Devasena , Pillai M Radhakrishna , Ramadas K 
Published: February 2025

Abstract

Background:
Oral cancer is a major health problem in India. Recently an increase in the oral cancer incidence among young individuals without any habits was observed, which may be due to Human Papilloma Virus (HPV). However, information on the prevalence of HPV in oral cancer in India is sparse. This study aims to document the frequency of HPV16 infection in oral squamous cell carcinoma (SCC) and to study its correlation with treatment outcome.

Methods:
Paraffin-embedded tissue blocks of 183 patients with SCC of the oral cavity were studied. HPV16 prevalence was detected by a polymerase chain reaction and expression of p16INK4a was analyzed by immunohistochemistry. This was correlated with clinical outcomes.

Results:
The prevalence of HPV 16 was 6.6% and all were carcinoma tongue. All HPV-positive patients showed intense expression of p16INK4a. The five-year overall survival (OS) and disease-free survival (DFS) for HPV positive patients were higher compared to HPV negative patients (100% versus 74.5% and 100% versus 70.8% respectively). The five-year OS and DFS for patients with p16INK4a intense expression were also higher compared to p16INK4a weak expression (91.2% versus 57.4% and 82% versus 22.5% respectively). Five-year OS and DFS of patients with HPV16 positivity and p16INK4a intense expression were significantly higher than patients with HPV negative and p16INK4a weak expression (100% versus 54.7% and 100% versus 22.5% respectively).

Conclusion:
The frequency of HPV16 positivity in oral cancer was low in this study with a site predilection to the oral tongue. p16INK4a expression did not correlate with HPV status. A better treatment outcome was observed in HPV-positive cancers. We also observed better treatment outcomes in patients with p16INK4A overexpression irrespective of HPV status.
Expression of the long noncoding RNA CASC2 in acute myeloid leukemia and its prognostic significance
Authors: Peng Sida , Yang Qingqing , Pan Yuhang , Li Huan , Wang Jiani , Hu Pan , Zhang Nana 
Published: February 2025

Abstract

Background:
Cancer susceptibility candidate 2 (CASC2) was found underexpressed in multiple types of human malignancies. However, the specific role of CASC2 in AML remains uncertain. The purpose of this study is to explore the expression of CASC2 in patients with AML and healthy donors and its prognostic significance in AML.

Methods:
Total RNA was isolated from bone marrow samples or peripheral blood samples of 87 patients with AML and 26 healthy adult donors. The expression of long noncoding RNA CASC2 was detected by quantitative real-time polymerase chain reaction. The association between CASC2 expression and other clinicopathological factors as well as its prognosis significance were analyzed.

Results:
The peripheral blood mononuclear cell (PBMC) expression level of CASC2 in AML was significantly lower than that in the healthy control cohort (P = 0.0048), and in the bone marrow samples, CASC2 was significantly upregulated in patients with AML after the achievement of CR (median value: 0.041, range: 0.015–0.064) compared with that at newly diagnosis (median value: 0.017, range: 0.008–0.041) (P = 0.002). The expression of CASC2 had a significant relationship with complete remission (P = 0.019). Survival data assessed by Kaplan–Meier curves showed that patients with lower CASC2 expression had shorter overall survival and disease-free survival than patients with higher CASC2 expression. Finally, Cox proportional hazards analysis demonstrated that CASC2 was an independent prognostic indicator for both OS (P = 0.013) and DFS (P = 0.001) of AML.

Conclusions:
LncRNA CASC2 may serve as a new molecular biomarker for the early diagnosis and of AML, and may be an independent prognostic factor affecting the survival of patients with AML.
Incidence of postoperative pulmonary complications and associated risk factors after major oncosurgeries: Prospective observational study
Authors: Agarwal Shilpi , Garg Rakesh , Bhatnagar Sushma , Mishra Seema , Bharati Sachidanand Jee , Gupta Nishkarsh , Kumar Vinod 
Published: February 2025

Abstract

Background:
Postoperative pulmonary complications (PPCs) are defined heterogeneously and have major adverse effects in increasing morbidity. Oncosurgeries themselves are complex, are of long duration, and extensive handling of body tissues occurs in them, leading to various complications including PPCs. So, we conducted this prospective study intending to find the incidence and risk factors for PPCs in patients undergoing major oncosurgeries.

Methods:
This prospective observational study was conducted after obtaining institutional ethical approval in patients undergoing major oncosurgeries. The demographic, preoperative, and intraoperative details were noted, and patients were followed in the postoperative period for the occurrence of PPC till discharge. Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) score was used to predict the occurrence of PPC. Data were analyzed using multivariable regression analysis for the risk factors, and the Chi-square trend was used to see the trend of PPC with the change in ARISCAT score.

Results:
The overall incidence of PPC in patients undergoing major oncosurgeries was 28.05%. The most common PPCs were respiratory insufficiency (19.2%) and atelectasis (17.6%). The highest incidence of PPC was found in thoracotomies (41.6%), followed by cytoreductive surgeries (40.6%). The risk factors for PPCs included body mass index (BMI) <18.5 or >25 kg/m2, smoking, use of nasogastric tube, age >60 years, and albumin <3.5 g/dL. Patients with low ARISCAT scores had a low incidence of PPC compared to those with high and intermediate ARISCAT scores.

Conclusion:
The incidence of PPC in patients undergoing major oncosurgeries was 28.05% in our study. The independent risk factors for PPC in oncological surgeries were BMI <18.5 kg/m2 or >25 kg/m2, use of nasogastric tube, age <60 years, serum albumin <3.5 g/dL, and smoking.
Giant basal cell carcinoma of the back – A tumor of the neglect
Authors: Malik Deepika , Bala S.V.S. , Pandey Laxman , Seam Rajeev K. 
Published: February 2025

Abstract
Giant basal cell carcinomas (GBCCs) represent only 0.5–1% of all basal carcinomas and are known to occur and behave differently than other basal cell carcinomas. We report a 93-year-old gentleman with GBCC of the back of superficial spreading histological type who we treated with radical radiotherapy with excellent local control. Nonaggressive histological subtypes of GBCC particularly the superficial type can be well managed with radiotherapy, especially in the elderly, and should be adequately utilized in carefully selected patients.
Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy
Authors: Arıkan Rukiye , Demircioğlu Özlem , Özgüven Salih , Demircan Nazım Can , Alan Özkan , Telli Tuğba Akın , Işık Selver , Başoğlu Tuğba , Çelebi Abdussamed , Yaşar Alper , Şahin Ceren Özge , Ercelep Özlem , Dane Faysal , Cimşit Canan , Yumuk Perran Fulden 
Published: February 2025

Abstract

Background:
We aimed to investigate the relationship between sarcopenia, which is defined by using psoas muscle index (PMI), and survival outcomes in patients with metastatic renal cell carcinoma (mRCC).

Methods:
This is a retrospective descriptive study of mRCC treated with first-line anti-vascular endothelial growth factor (anti-VEGF) therapy. The prognostic significance of PMI for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Additionally, the skeletal muscle index (SMI) was calculated and correlation analysis was performed between PMI and SMI.

Results:
Eighty-eight patients with a median age of 60 years (interquartile range [IQR], 51–66) were included. Median PFS with first-line treatment was 6 (95% confidence interval [CI]: 2.9–9.03) months and median OS was 17 (95% CI: 10.6–23.03) months in all patients. Mean PMI was 5.71 (standard deviation [SD]: ±1.41) in women and 8.30 (SD: ±2.04) in men. Forty-seven (53.4%) patients according to PMI and 49 (55.6%) patients according to SMI were accepted as sarcopenic. The overall correlation between SMI and PMI was strong (rs = 0.73). PFS was numerically shorter in the low-PMI and low-SMI groups than the high-PMI and high-SMI groups, but it did not reach statistical significance. In univariate analyses, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, anti-VEGF agent option, PMI, and SMI were significant prognostic factors for OS (P < 0.05 each). In multivariate analyses for OS, while IMDC score (P < 0.001) and PMI (P = 0.04) were significant independent prognostic factors according to multivariate analysis-1, IMDC score (P < 0.001) and SMI (P = 0.01) were significant independent prognostic factors according to multivariate analysis-2.

Conclusions:
Pretreatment PMI has a strong correlation with SMI and is an independent prognostic factor for OS in patients with mRCC.